Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.
Set Alert for Articles By Ian Haydock

Latest From Ian Haydock

Takeda Alliance Boosts Liver Disease Venture Ambys’s $140m Launch

Takeda is investing in newly launched serious liver disease company Ambys Medicines to support the advancement of the US venture’s platform and pipeline, in line with its core strategic therapeutic priorities.

Liver & Hepatic Japan

What A Whiz! Takeda Spins Off Discovery Op Axcelead Into New Fund

Takeda has spun off into a new joint investment fund selected drug discovery operations in Japan that had been shifted to the new Axcelead business last year, further honing its focus ahead of the Shire acquisition and in a move to foster a more effective early-stage ecosystem in the country.

Japan Research and Development Strategies

Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In

Ascletis was the first with a new listing under new Hong Kong rules, but BeiGene also sold shares on the HKEX; the companies raised more than $1bn combined. Also, TherapeuticsMD sold stock in the US to commercialize Imvexxy, Curon raised the latest $150m VC mega-round, and NewLink cut jobs in R&D refocus.

Financing Business Strategies

Global First As Japan Starts iPS Cell Trial In Parkinson's

Building on its national expertise in the area, Japan is starting the first clinical trial globally to assess the use of iPS-derived cells for the treatment of Parkinson’s disease.

Japan Clinical Trials

Shire Integration Prep Progresses As Takeda Logs Solid 1Q

Takeda and Shire are already discussing their planned integration across multiple areas, but until the deal closes formally the Japanese firm stresses it is business as usual, as it reports solid underlying growth in the fiscal first quarter, driven by core products.

M & A Japan

Chugai Explores New Tech In Strategic Push For Innovation

Chugai is investing in new R&D infrastructure and exploring disruptive technologies as part of a strategic push to build its global drug discovery capabilities.

Research and Development Strategies Biologics
See All